Trial · NCT05946551
Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial
NCT05946551, Phase 3, Terminated, Emory University; results first posted 2025-07-17
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial. Trials, record NCT05946551. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05946551
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial
- NCT number
- NCT05946551
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 5 participants, actual
- Lead sponsor
- Emory University
- Conditions
- COVID-19
- Interventions
- Cetirizine, Famotidine, Cetirizine Placebo, Famotidine Placebo
- First posted
- 2023-07-14
- Last updated
- 2025-07-17
- Results first posted
- 2025-07-17
Source ClinicalTrials.gov
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants That Had Any Confusion Over How to Take the Study Drug, Including Which Pill to Take, When to Take it, or How Many to Take | End of the Treatment Phase at 12 weeks | The number of participants that had any confusion over how to take the study drug, including which pill to take, when to take it, or how many to take will be recorded as part of the end-of-study survey. |
| Primary | Number of Participants That Had Trouble Adhering to the Study Drug Schedule | End of the Treatment Phase at 12 weeks | The number of participants that had trouble adhering to the study drug schedule will be recorded as part of the end-of-study survey. |
| Primary | Number of Participants That Had Any Difficulty Using the REDCap Interface. | End of the Treatment Phase at 12 weeks | The number of participants that had any difficulty using the REDCap interface will be recorded as part of the end-of-study survey. |
| Primary | Number of Participants That Prefer Participating in This Virtual Study | End of the Treatment Phase at 12 weeks | The number of participants that prefer participating in this virtual study compared to participating in an in-person study hosted at a medical center will be recorded as part of the end-of-study survey. |
| Primary | Number of Participants Satisfied With Their Opportunities to Interact With Study Staff | End of the Treatment Phase at 12 weeks | The number of participants satisfied with their opportunities to interact with study staff will be recorded as part of the end-of-study survey. |
| Primary | Number of Participants That Felt They Could Reach Study Staff if Needed | End of the Treatment Phase at 12 weeks | The number of participants that felt they could reach study staff if needed will be recorded as part of the end-of-study survey. |
| Primary | Number of Participants That Felt That Study Staff Was Available and Easy to Contact to Report Any Adverse Effects | End of the Treatment Phase at 12 weeks | The number of participants that felt that study staff was available and easy to contact to report any adverse effects that they experienced from the medication will be recorded as part of the end-of-study survey. |
| Primary | Number of Participants That Felt That the Amount of Information Collected in Each Series of Surveys Was Acceptable | End of the Treatment Phase at 12 weeks | The number of participants that felt that the amount of information collected in each series of surveys was acceptable will be recorded as part of the end-of-study survey. |
| Primary | Number of Participants That Felt That the Frequency in Which the Information Was Collected Was Acceptable | End of the Treatment Phase at 12 weeks | The number of participants that felt that the frequency in which the information was collected was acceptable will be recorded as part of the end-of-study survey. |
| Primary | Improvement Rating | End of the Treatment Phase at 12 weeks | Participants will be asked how much they feel they improved from this treatment over the last 12 week using a scale from 1 to 5, with 5 being complete improvement (better outcome) and 1 being no improvement. |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 registered outcomesOutcomes20
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants That Had Any Confusion Over How to Take the Study Drug, Including Which Pill to Take, When to Take it, or How Many to Take | End of the Treatment Phase at 12 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Number of Participants That Had Trouble Adhering to the Study Drug Schedule | End of the Treatment Phase at 12 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Number of Participants That Had Any Difficulty Using the REDCap Interface. | End of the Treatment Phase at 12 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Number of Participants That Prefer Participating in This Virtual Study | End of the Treatment Phase at 12 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Number of Participants Satisfied With Their Opportunities to Interact With Study Staff | End of the Treatment Phase at 12 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Number of Participants That Felt They Could Reach Study Staff if Needed | End of the Treatment Phase at 12 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Number of Participants That Felt That Study Staff Was Available and Easy to Contact to Report Any Adverse Effects | End of the Treatment Phase at 12 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Number of Participants That Felt That the Amount of Information Collected in Each Series of Surveys Was Acceptable | End of the Treatment Phase at 12 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Number of Participants That Felt That the Frequency in Which the Information Was Collected Was Acceptable | End of the Treatment Phase at 12 weeks | Participants | COUNT_OF_PARTICIPANTS | |
| PRIMARY | Improvement Rating | End of the Treatment Phase at 12 weeks | Score on a scale | MEAN |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 outcomesResults by group40
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants That Had Any Confusion Over How to Take the Study Drug, Including Which Pill to Take, When to Take it, or How Many to Take | HRA Treatment Arm | 0 | Participants | ||
| Number of Participants That Had Any Confusion Over How to Take the Study Drug, Including Which Pill to Take, When to Take it, or How Many to Take | Placebo Arm | 0 | Participants | ||
| Number of Participants That Had Trouble Adhering to the Study Drug Schedule | HRA Treatment Arm | 0 | Participants | ||
| Number of Participants That Had Trouble Adhering to the Study Drug Schedule | Placebo Arm | 0 | Participants | ||
| Number of Participants That Had Any Difficulty Using the REDCap Interface. | HRA Treatment Arm | 0 | Participants | ||
| Number of Participants That Had Any Difficulty Using the REDCap Interface. | Placebo Arm | 0 | Participants | ||
| Number of Participants That Prefer Participating in This Virtual Study | HRA Treatment Arm | 3 | Participants | ||
| Number of Participants That Prefer Participating in This Virtual Study | Placebo Arm | 2 | Participants | ||
| Number of Participants Satisfied With Their Opportunities to Interact With Study Staff | HRA Treatment Arm | 3 | Participants | ||
| Number of Participants Satisfied With Their Opportunities to Interact With Study Staff | Placebo Arm | 2 | Participants |
1 to 10 of 40Source ClinicalTrials.gov
See all 40 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | HRA Treatment Arm | 3 | |
| Overall Study | STARTED | Placebo Arm | 2 | |
| Overall Study | COMPLETED | HRA Treatment Arm | 3 | |
| Overall Study | COMPLETED | Placebo Arm | 2 | |
| Overall Study | NOT COMPLETED | HRA Treatment Arm | 0 | |
| Overall Study | NOT COMPLETED | Placebo Arm | 0 |
Source ClinicalTrials.gov
Adverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Sore neck | Musculoskeletal and connective tissue disorders | HRA Treatment Arm | 1 | 3 | |
| other | Sore neck | Musculoskeletal and connective tissue disorders | Placebo Arm | 0 | 2 | |
| other | Upper respiratory infection | Respiratory, thoracic and mediastinal disorders | HRA Treatment Arm | 2 | 3 | |
| other | Upper respiratory infection | Respiratory, thoracic and mediastinal disorders | Placebo Arm | 2 | 2 | |
| other | Herpes Zoster | Infections and infestations | HRA Treatment Arm | 1 | 3 | |
| other | Herpes Zoster | Infections and infestations | Placebo Arm | 0 | 2 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | HRA Treatment Arm | 0 | 3 |
| Total, all-cause mortality | Placebo Arm | 0 | 2 |
| Total, other adverse events | HRA Treatment Arm | 3 | 3 |
| Total, other adverse events | Placebo Arm | 2 | 2 |
| Total, serious adverse events | HRA Treatment Arm | 0 | 3 |
| Total, serious adverse events | Placebo Arm | 0 | 2 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons16
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| HRA Treatment Arm vs Placebo Arm: Proportion of Survey Completion | Trial comparisons |
| HRA Treatment Arm vs Placebo Arm: Number of Participants That Prefer Participating in This Virtual Study | Trial comparisons |
| HRA Treatment Arm vs Placebo Arm: Number of Participants That Felt That the Frequency in Which the Information Was Collected Was Acceptable | Trial comparisons |
| HRA Treatment Arm vs Placebo Arm: Proportion of Voluntary Termination | Trial comparisons |
| HRA Treatment Arm vs Placebo Arm: Number of Participants Satisfied With Their Opportunities to Interact With Study Staff | Trial comparisons |
| HRA Treatment Arm vs Placebo Arm: Number of Participants That Felt That Study Staff Was Available and Easy to Contact to Report Any Adverse Effects | Trial comparisons |
| HRA Treatment Arm vs Placebo Arm: Proportion of Lost to Follow Up (LFUP) | Trial comparisons |
| HRA Treatment Arm vs Placebo Arm: Proportion of Study Drug Adherence | Trial comparisons |
| HRA Treatment Arm vs Placebo Arm: Number of Participants That Felt That the Amount of Information Collected in Each Series of Surveys Was Acceptable | Trial comparisons |
| HRA Treatment Arm vs Placebo Arm: Number of Participants That Had Any Confusion Over How to Take the Study Drug, Including Which Pill to Take, When to Take it, or How Many to Take | Trial comparisons |
1 to 10 of 16
See all 16 trial comparisonsTests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05946551
GET https://conductscience.org/api/trials/v1/NCT05946551/results?page=2